Comparative Pharmacology
Head-to-head clinical analysis: ASTAGRAF XL versus CELLCEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTAGRAF XL versus CELLCEPT.
ASTAGRAF XL vs CELLCEPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin inhibitor that binds to FKBP-12, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NFAT, which reduces T-cell activation and cytokine production (e.g., IL-2).
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Initial oral dose of 0.1-0.15 mg/kg/day divided every 12 hours, with subsequent adjustments based on trough levels. Typical maintenance dose 0.05-0.15 mg/kg/day.
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 43 hours (range 15.8–68.6 hours) in adult kidney transplant recipients. This long half-life supports once-daily dosing. In liver transplant patients, half-life ranges from 12 to 42 hours.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Primarily fecal (94.6%) via biliary elimination. Renal excretion accounts for approximately 2.4% of the dose, mainly as metabolites. Less than 1% is excreted unchanged in urine.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Category C
Category C
Immunosuppressant, Calcineurin Inhibitor
Immunosuppressant